Smart Biopsy Market to reach a market size of $3.2 billion by 2025
The Global Smart Biopsy Market size is expected to reach $3.2 billion by 2025, rising at a market growth of 5.3% CAGR during the forecast period.
Smart Biopsy Market(firmenpresse) - According to a new report Global Smart Biopsy Market, published by KBV Research, The Global Smart Biopsy Market size is expected to reach $3.2 billion by 2025, rising at a market growth of 5.3% CAGR during the forecast period.
In the application segment, breast cancer sub-segment dominated the market in 2018. The reason being, it's the most common cancer diagnosed among women over the age of 45. This cancer grows either in lobules (glands that produce milk) or in ducts that usually form in breast cells. The Skin cancer market is anticipated to grow at a CAGR of 5.8% during (2019-2025). The Prostate cancer market is poised to grow at a CAGR of 6.26% during the forecast period.
North America dominated the smart biopsy device market in 2018. This dominance is linked to increased cancer prevalence, increased awareness of cancer screening, the existence of well-established healthcare facilities, and the presence of early tests and treatments in the region. The Europe market is expected to witness a CAGR of 4.9% during (2019-2025). The Asia- Pacific region is anticipated to experience the highest growth rate of 6.6% during the forecast period. This rapid growth rate can be attributed to extensive government initiatives, healthcare spending, cancer awareness campaigns, and the availability of technologically advanced smart biopsy devices.
Structural Insights: https://www.kbvresearch.com/smart-biopsy-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Danaher Corporation, Argon Medical Devices, Inc., Cardinal Health, Inc., Canon, Inc. (Canon Medical Systems Corporation), Boston Scientific Corporation, Olympus Corporation, Hologic, Inc., B. Braun Melsungen AG, Cook Medical, Inc. (Cook Group) and Medtronic Plc.
Recent Strategies Deployed in Smart Biopsy Market
» Collaborations, Partnerships and Agreements:
Jun-2019: Argon Medical signed a licensing agreement with Hatch Medical, a US-based medical device incubator and technology brokerage firm. Under this agreement, Hatch has provided the license of manufacturing and distributing rights to Argon for its family of liver access products, including the Scorpion Transjugular Intrahepatic Portasystemic Shunt (TIPS) Access Systems. This system complements to its TLAB transjugular liver biopsy system.
Jan-2019: Olympus came into partnership with USC for advancing research into cancer prevention, diagnosis, and treatment with the help of precision medicine. This partnership demonstrates the clinical utility of new technologies, which combines the workflow of primary diagnosis and surgical biopsy with microscopic cellular and molecular characterization.
Jun-2018: Olympus collaborated with Hitachi Healthcare Americas, a leader in ultrasound and CT/MRI medical imaging. In this collaboration, they will distribute the ARIETTA 850, a new OLED monitor and efocusing technology that enhances the ultrasound images and allows for more detailed observation.
Mar-2018: Hologic teamed up with Philips for offering care professionals’ integrated solutions including advanced informatics and services for screening, diagnostic imaging modalities, and diagnosis and treatment of women. This collaboration integrates Philips' portfolio of MRI, CT, ultrasound, X-Ray Systems, etc. with Hologic’s innovative mammography technologies.
Jan-2018: Olympus and Ruhof signed an agreement for the distribution of Ruhof’s Guardian Endoscope Single-use and Disposable Valve Set. These sets contain suction, one/air water, biopsy valve and helps in prevention of cross contamination.
» Acquisition and Mergers:
Nov-2019: Canon Medical, a subsidiary of Canon, Inc., announced an agreement to acquire 70% stake in Quality Electrodynamics (QED), a US-based diagnostic imaging company. QED is engaged in the development of MRI technology for radiofrequency coils. The acquisition helps in capturing the diagnostic images of the human anatomy.
Aug-2019: Boston Scientific acquired BTG PLC that develops and commercializes the products used in minimally invasive procedures targeting vascular diseases and cancer.
May-2019: Argon Medical took over Mana-Tech, Ltd., a distributor of radiology consumables and biopsy products in U.K. This acquisition helps Argon in expanding its reach to U.K. by offering its wide range of products like interventional radiology, guidewires, vascular surgery products, etc. to the customers in U.K.
Oct-2018: Boston Scientific took over Augmenix Inc., developer of the SpaceOAR Hydrogel System for help in reducing the common and deliberating side effects, which men may experience after receiving radiotherapy to treat prostate cancer.
Sep-2018: Hologic signed a definitive agreement to acquire Focal Therapeutics, a medical device maker. The acquisition helps Hologic in expanding its ability to help women diagnosed with breast cancer from screening with the help of surgery.
Jul-2018: Hologic took over Faxitron Bioptics, a leader in digital specimen radiography. The acquisition broadens the portfolio of Hologic's Breast Health. The portfolio of Faxitron includes digital specimen radiography, breast lesion localization, and sentinel lymph node biopsy.
Apr-2018: Boston Scientific announced the acquisition of nVision Medical Corporation, a privately-held company focused on women's health. NVision devices collect cells that correlate with post-surgery definitive diagnosis of ovarian cancer while testing.
Apr-2018: Olympus signed an agreement to acquire lithotripsy system from Cybersonics in order to extend its urology portfolio.
» Product Launches:
Apr-2019: Hologic launched Trident HD specimen radiography system in the U.S. This system delivers improved workflow and enhanced image quality with instant sample verification during breast-conserving surgeries and stereotactic breast biopsies. This system has the feature of biggest detector, which provides clinicians a complete image of large breast surgical specimens and a variety of biopsy and surgical samples.
Mar-2019: Canon Medical, a subsidiary of Canon, Inc., launched 33 MHz ultra-high frequency linear transducer on Aplio i800 for providing spatial resolution and extremely fine detail in the near field. It offers detail for B-mode and Color Flow imaging and useful in surgical planning.
Feb-2019: Canon Medical, a subsidiary of Canon, Inc., introduced AiCE (Advanced intelligent Clear IQ Engine), a deep convolutional neural network (DCNN) image reconstruction technology for computed tomography (CT). This technology uses deep learning technology in order to differentiate the signal from noise so that it can remove the noise while it preserves the true signal.
Nov-2018: Canon Medical, a subsidiary of Canon, Inc., released the Alphenix platform, its next-generation of interventional systems. This platform of system includes all-new features, which enables the clinicians to provide the images with clarity and precision without compromising the workflow and prioritizing the low dose.
Oct-2018: Leica Biosystems, a subsidiary of Danaher, launched MammoPort, the first integrated specimen containment and transport system for breast tissue biopsies. This system eliminates the unnecessary tissue manipulation and calcification separation completely and maintains the critically important tissue orientation, size and integrity.
» Expansions:
Nov-2019: Boston Scientific opened a new technology center at its Ballybrit site in Galway. This expansion is focused towards the development of the products in the areas of endoscopy, interventional cardiology, and peripheral interventions.
May-2019: Canon Medical, a subsidiary of Canon, Inc., installed Aquilion One Genesis, one of the first computed tomography (CT) scanners with artificial intelligence (AI) functionality in Europe. Through this installation, the company expanded its reach in Europe.
Global Smart Biopsy Market Segmentation
By Application
Breast cancer
Skin cancer
Liver cancer
Prostate cancer and
Others
By Geography
North America
US
Canada
Mexico
Rest of North America
Europe
Germany
UK
France
Russia
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific
LAMEA
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA
Companies Profiled
Danaher Corporation
Argon Medical Devices, Inc.
Cardinal Health, Inc.
Canon, Inc. (Canon Medical Systems Corporation)
Boston Scientific Corporation
Olympus Corporation
Hologic, Inc.
B. Braun Melsungen AG
Cook Medical, Inc. (Cook Group)
Medtronic Plc.
Smart Biopsy Market Related Reports:
North America Market
Europe Market
Asia Pacific Market
LAMEA Market
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
KBV Research is Knowledge Based Value Research, which is a global brand and consulting firm serving all kinds of business verticals, government and non-governmental organizations, and not-for-profit organizations. Our motto is to extend our services that will have a lasting impact on our clients who trust us with their business goals. KBV Research is a global market research and consulting company offering syndicated and custom market research reports with exhaustive industry analysis.
244 Fifth Avenue, Suite 1407
New York, N.Y. 10001
United States (U.S)
Tel: +1 (646) 661-6066
Email: info(at)kbvresearch.com
Datum: 31.12.2019 - 09:42 Uhr
Sprache: Deutsch
News-ID 604676
Anzahl Zeichen: 9837
contact information:
Contact person: Prity Singh
Town:
New York
Phone: 6466616066
Kategorie:
Healthcare
Typ of Press Release: Product
type of sending: don't
Date of sending: 31`.12.2019
Diese Pressemitteilung wurde bisher 291 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Smart Biopsy Market to reach a market size of $3.2 billion by 2025"
steht unter der journalistisch-redaktionellen Verantwortung von
KBV Research (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
